Описание
Статус выполнения
completedResults
Ход выполнения
Заболевания
Цели
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.
Организация, проводящая КИ
Clear Creek Bio, Inc.
Фаза КИ
II
Количество пациентов
17
Источник